| Moffitt

Can Adding Immunotherapy to Chemo Benefit More Cervical Cancer Patients?

Phase 3 trial results suggest adding pembrolizumab to chemotherapy improved survival for those with advanced or recurrent disease

Cell Therapy Superior to Standard of Care for Multiple Myeloma

Phase 3 trial results show improved response rate and reduced risk of disease progression

Treatment Innovations in Rectal, Lung and Brain Cancers

New research shows benefit of de-escalating and targeting therapies to improve outcomes

Adding Inhibitor to Hormonal Therapy Reduces Risk of Breast Cancer Recurrence

Phase 3 trial results could be practice changing for both men and women

Moffitt Scientists Share Innovative Clinical Research at ASCO

The American Society of Clinical Oncology Annual Meeting attracts more than 40,000

New Study Shows Promise for Difficult to Treat Brain Metastases

First in human trial is recruiting patients with leptomeningeal disease from triple- negative or HER2 positive breast cancers

Photo of the Week: Breakthroughs on Display

Moffitt Scientific Symposium attracts a record-breaking 400 attendees

The Truth About Clinical Studies: The Most Advanced Cancer Care at Moffitt Cancer Center

Learn more about some common misconceptions that prevent patients from joining clinical trials.

Personalized mRNA Vaccine Shows Early Promise for Pancreatic Cancer

In a recently published phase 1 trial, half of patients had longer recurrence-free survival

Hematologist Trains at Moffitt, Hoping to Benefit Armenians

Through a visiting physician program, a doctor is learning the intricacies of an allogeneic BMT procedure and care to help his home country

Improving Cancer Care for People with HIV

Moffitt’s HIV clinic reduces burdens for patients fighting for their health on two fronts

Mobile Monitoring: Making Cancer Care More Accessible

Moffitt researchers and clinicians are taking telehealth to the next level

Global Clinical Trial Explores New Combination Therapy for Metastatic Breast Cancer

The ongoing VIKTORIA-1 Phase 3 trial targets patients with hormone receptor positive, HER2 negative breast cancer

Navigating Racial and Ethnic Criteria Appropriately Could Boost Clinical Trial Eligibility

According to researchers, criteria may pose additional barriers to minority cancer patients

CAR T Shows Promise for Adults with Acute Lymphoblastic Leukemia

Kids under 5 have the highest risk for ALL, but it’s more deadly in adults.

Phase 2 Bladder Cancer Trial Shows Promising Results

Updated data were presented at the 2022 SITC Annual Meeting

Combining Targeted Radiotherapy with Immunotherapy May Improve Outcomes for Cervical Cancer Patients

Interim results from phase 2 clinical trial reveal responses to combination therapy

Moffitt Radiation Oncology Experts Share the Latest in Treatment and Research

The American Society for Radiation Oncology annual meeting is the largest conference of its kind in the world

Moffitt Cancer Center Expanding to South Hillsborough County

New facility expected to serve thousands more patients and create 150 jobs

Enhertu Gives Patients with HER2-Low Breast Cancer a New Option

Moffitt was part of the clinical trial that led to the drug’s recent FDA approval

Certain Patients with Breast Cancer May Not Need Radiation after Surgery

New results show luminal A breast cancer may benefit from endocrine therapy alone

New Data May Change Approach to Treating Multiple Myeloma, Ewing Sarcoma and Breast Cancer

ASCO studies show benefit to reevaluating current standard of care for these diseases

Studies Highlight Optimizing Therapy in Colon and Breast Cancer

Better targeting treatment approaches can greatly reduce toxicities

Adding Ibrutinib to Standard of Care Improves Progression Free Survival in Older Patients with Mantle Cell Lymphoma

However, experts say it may be too soon to say new phase 3 trial data is practice changing

Moffitt Researchers Use Explainable AI to Investigate and Predict the Survival Efficacy of Immunotherapy Drug

Data presented at ASCO help researchers get a deeper understanding of immune checkpoint inhibitors efficiency in patients

Genomics, Not Specific Tumor Sites, Could Influence Future Cancer Treatment

New research suggests LAG3 could be the next big target for personalized therapy

Next Generation of Cancer Researchers Highlight Expertise

Moffitt Cancer Center’s Scientific Symposium gives clinical and research trainees the opportunity to feature innovative studies

Report Shows COVID’s Impact on Cancer Care, Research

Nearly 10 million cancer screenings were missed between January to July of 2020

FDA Approves “Glowing Tumor” Drug for Ovarian Cancer Surgery

Fluorescent dye helps surgeons better identify hard-to-find cancer cells

New Radioactive Treatment Could Be Game Changer for Prostate Cancer

Norman Busciglio says the targeted nuclear medicine has kept him pain and disease free for almost two years

‘Off the Shelf’ CAR T Shows Promise

New study results find the therapy is effective for certain lymphoma patients

Moffitt Scientists Present New Clinical Research at ASCO

The American Society of Clinical Oncology Annual Meeting is one of the largest oncology conferences in the world

Can the Herpes Virus Fight Triple-Negative Breast Cancer?

More than 90% of women injected with the virus are alive up to three years later

FDA Approves CAR T to Help Patients with Relapsed Multiple Myeloma

For one patient, the therapy, made available to him through a clinical trial, was his last resort

New CAR T Therapy Tested for Multiple Myeloma

The cellular targets the B-cell maturation antigen found on malignant plasma cells

CAR T Brings Hope for Leukemia Patients, Challenges for Researchers

Phase 1 THINK study laid important groundwork for future CAR T trials

New Combination Therapy Shows Promise for Leukemia Patients

Early phase trial finds magrolimab plus chemotherapy effective in acute myeloid leukemia patients

Once a Fighter, Always a Fighter

Former prosecutor battles stage 4 lung cancer with help of investigational immunotherapy

‘My Reason Why is Because I Can’

Runner Alvaro Zamora shares why he participates in Miles for Moffitt

Speeding Up Cellular Immunotherapy

New ‘off the shelf’ CAR T product shows promise in phase 1 study

Melanoma Immunotherapy Offers Hope for Lung Cancer

Patients’ own magnified army of T cells used to treat non-small cell lung cancer

In the Eye of the COVID-19 Storm

How yearly hurricane planning helped Moffitt be prepared for the pandemic

Repurposing Drugs to Fight COVID-19

World Health Organization launches global trials on four possible treatments

Innovative Trial Tackles Early Stage Breast Cancer

Immunotherapy plus chemotherapy shows promising results for certain early stage breast cancers

Can Gene Editing Improve Cellular Immunotherapy?

New study suggests CRISPR edited cells can be used to enhance T cell receptor therapy

Open Your Eyes and Relax

Moffitt develops virtual reality app to improve patients’ sleep.

Moffitt Launches Innovative Trial for Brain-Metastatic Breast Cancer

The therapy includes a three-part immunotherapy combination to shrink tumors.

The Power of CAR T in Solid Tumor Treatment

CAR T therapy involves a patient’s own T cells that have been genetically engineered to target a patient’s own specific cancer.

‘A Clinical Trial Saved My Life’

After melanoma metastasized to his brain, Larry Thomason was given 10 months to live.

Clinical Trial Brings Hope to Lung Cancer Patient

Last year, Lee was diagnosed with stage 4 metastatic lung cancer that had spread to her brain and spine.

Clinical Research and Patient Safety

As a National Cancer Institute-designated cancer center, Moffitt is charged with conducting investigator-initiated trials, which are designed and mana ...

Clinical Research Unit: A Source of Hope

Look in Moffitt’s Clinical Research Unit (CRU), and you’ll find it in the work of a united team doing whatever is necessary to transform hope into rea ...

Investigational Drug Service

The Investigational Drug Services pharmacy manages the drugs needed for approximately 300 various early-phase clinical trials administered in Moffitt’ ...

Herpes Virus Can be Used to Treat Melanoma. Which Cancer is Next?

Since the approval of talimogene laherparepvec (T-VEC, Imlygic®) in 2015, Moffitt has been using this modified form of the herpes virus as a standard ...

Saving Lives After Death

Gail Porter was the first patient to enroll in Moffitt's rapid tissue donation program.

The ReMissions Shine Light on Moffitt’s Mission

“We listen to each other, work together and make harmony together.”

Filter Features Results

56 Articles Found